Evidence map›Paper›PMID 20176693›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2010

European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document.

M Arbyn, A Anttila, J Jordan, G Ronco, U Schenck, N Segnan, H Wiener, A Herbert, L von Karsa

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Trial
  12. Trial
  13. [Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M ArbynUnit of Cancer Epidemiology/Belgian Cancer Center, Scientific Institute of Public Health, Brussels, Belgium.
A AnttilaMass Screening Registry, Finnish Cancer Registry, Helsinki, Finland.
J JordanBirmingham Women's Hospital, Birmingham, UK.
G RoncoCancer Epidemiology Unit, Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy.
U SchenckInstitute of Pathology, Technical University, Munich, Germany.
N SegnanCancer Epidemiology Unit, Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy.
H WienerDepartment of Clinical Pathology and Histopathology, Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
A HerbertHistopathology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
L von KarsaQuality Assurance Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France. Electronic address: karsal@iarc.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

European Guidelines for Quality Assurance in Cervical Cancer Screening have been initiated in the Europe Against Cancer Programme. The first edition established the principles of organised population-based screening and stimulated numerous pilot projects. The second multidisciplinary edition was published in 2008 and comprises approximately 250 pages divided into seven chapters prepared by 48 authors and contributors. Considerable attention has been devoted to organised, population-based programme policies which minimise adverse effects and maximise benefits of screening. It is hoped that this expanded guidelines edition will have a greater impact on countries in which screening programmes are still lacking and in which opportunistic screening has been preferred in the past. Other methodological aspects such as future prospects of human papillomavirus testing and vaccination in cervical cancer control have also been examined in the second edition; recommendations for integration of the latter technologies into European guidelines are currently under development in a related project supported by the European Union Health Programme. An overview of the fundamental points and principles that should support any quality-assured screening programme and key performance indicators are presented here in a summary document of the second guidelines edition in order to make these principles and standards known to a wider scientific community.

Indexed as

Mass ScreeningEuropeFemaleHumansQuality Assurance, Health CareUterine Cervical DysplasiaUterine Cervical Neoplasms

Identifiers

PMID20176693
PMCPMC2826099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.